National Saudi Consensus Statement on the Management of Atopic Dermatitis (2021).
Mohammad I FataniAfaf A Al SheikhMohammed A AlajlanRuaa S AlharithyYousef BinamerRayan G AlbarakatiKhalidah A AlenziAmr M KhardalyBedor A AlomariHajer Y AlmudaiheemAhmed Al-JedaiMaysa Tariq Yousef EshmawiPublished in: Dermatology and therapy (2022)
Atopic dermatitis (AD) is a chronic inflammatory skin disease with an increasing prevalence regionally and globally. It is characterized by intense itching and recurrent eczematous lesions. With the increase in the availability of treatment options for healthcare practitioner and patients, new challenges arise for treatment selection and approach. The current consensus statement has been developed to provide up-to-date evidence and evidence-based recommendations to guide dermatologists and healthcare professionals managing patients with AD in Saudi Arabia. By an initiative from the Ministry of Health (MOH), a multidisciplinary work group of 11 experts was convened to review and discuss aspects of AD management. Four consensus meetings were held on January 14, February 4, February 25, and March 18 of 2021. All consensus content was voted on by the work group, including diagnostic criteria, AD severity assessment, comorbidities, and therapeutic options for AD. Special consideration for the pediatric population, as well as women during pregnancy and lactation, was also discussed. The present consensus document will be updated as needed to incorporate new data or therapeutic agents.
Keyphrases
- atopic dermatitis
- healthcare
- clinical practice
- quality improvement
- end stage renal disease
- ejection fraction
- chronic kidney disease
- public health
- mental health
- prognostic factors
- pregnant women
- metabolic syndrome
- peritoneal dialysis
- type diabetes
- health information
- insulin resistance
- human milk
- electronic health record
- skeletal muscle
- artificial intelligence
- saudi arabia
- smoking cessation
- breast cancer risk